Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — FY2026 Earnings Presentation
19 slides from Emvision Medical Devices's earnings presentation, August 2026
Slide 1: FY26 Results Presentation
EMVision Medical Devices Ltd ASX:EMV FY26 Results Presentation August 2026
Slide 2: Disclaimer
DISCLAIMER This Presentation has been prepared by EMVision Medical Devices Ltd (ACN 620 388 230) (the “Company”). This Presentation is for information purposes only and should be read in conjunction with the most recent financial reports and other documents lodged by the Company with the Australian
Slide 3: Introduction to EMVision
INTRODUCTION TO EMVISION Building a new category of point of care neurodiagnostic devices for acute neurological emergencies emu In-hospital device Novel Technology Differentiated Solution – Foundation research at the University of Queensland – World-first portable and rapid neurodiagnostic solution
Slide 4: Why We Are Starting in Stroke
WHY WE ARE STARTING IN STROKE Stroke remains a large and growing cause of mortality and disability globally 1 in 4 people will have a stroke in their lifetime Time is brain Around two-thirds of survivors suffer permanent disability Every minute that a stroke goes untreated, approximately 2 million b
Slide 5: Stroke and TBI Require Urgent Diagnosis
STROKE AND TBI REQUIRE URGENT DIAGNOSIS Conventional CT imaging is critical in stroke and TBI diagnosis but not widely accessible at the point of care Mobile Stroke Units (MSUs) are custom-built ambulances fitted with a mobile CT Portable Lightweight Cost Non- effective ionizing Conventional CT Mobi
Slide 6: EMVision in the Stroke Care Pathway
EMVISION IN THE STROKE CARE PATHWAY Rapid neurodiagnostic insight at the point of care to accelerate decision making and care pathway activation Stroke onset (pre-hospital) Hospital arrival & triage Monitoring & recovery In-field stroke detection & Initial scan in emergency Routine monitoring in ICU
Slide 7: Market Opportunity
MARKET OPPORTUNITY Multi-billion-dollar addressable market for emu and First Responder devices US First Strategy emu (In-Hospital) First Responder (Pre-Hospital) US Stroke Belt: High Priority Targets US Stroke Belt: High Priority Targets Initial Launch Strategy – Concentrated, high need geography –
Slide 8: Highlights & Financials
Highlights & Financials 8 Advanced prototype pictured
Slide 9: FY2026 Highlights
FY2026 HIGHLIGHTS Significant progress across clinical programs, product development and commercial priorities 1 emu (in-hospital) 2 First Responder 3 Commercial & Market (pre-hospital) • Pivotal (Validation) Trial, to support FDA De • Aeromedical Retrieval Study completed, with • Strong balance she
Slide 10: Profit and Loss
PROFIT AND LOSS For the year ended 30 June 2026 AUD FY26 FY25 Income Commentary Grant income 3,269,373 1,749,240 Other income 82,984 164,500 • Total non-dilutive grant income and R&D R&D rebate 5,005,595 3,137,983 tax incentive income of $8.3 million for the year. Interest income 491,133 576,710 • T
Slide 11: Balance Sheet
BALANCE SHEET As at 30 June 2026 AUD 30 June 2026 30 June 2025 Cash 17,103,760 10,456,814 Commentary Other financial assets - 73,651 • Cash balance increased following completion of Other current assets 295,924 272,084 $14.0 million capital raising (pre-costs) in H1 FY26. R&D receivable 4,296,599 3,
Slide 12: Cashflow
CASHFLOW For the year ended 30 June 2026 AUD FY26 FY25 Receipts from grants (inc. GST) 7,375,124 3,856,285 Commentary Receipts of other income 37,017 178,297 Payments to suppliers & employees (inc. GST) (13,983,498) (12,431,314) • Proceeds from issuance of shares reflect Interest received 425,966 57
Slide 13: Outlook
ee | Outlook
Slide 14: Outlook
OUTLOOK Key priorities for the next twelve months emu In-Hospital First Responder Pre-Hospital Commercial & Corporate Complete pivotal trial enrolment Build commercial production equivalent units Prepare for US launch Continue to hit recruitment milestones, culminating in First Responder production
Slide 15: emu Pathway
emu PATHWAY Pivotal (Validation) Trial gaining momentum Recruitment Surpassing Key Milestones Adding Ischaemia Detection Feature • Recently introduced enrolment acceleration initiatives supporting • Preparations are underway to add acute ischaemia detection to Pivotal Trial. recruitment momentum. •
Slide 16: First Responder Pathway
FIRST RESPONDER PATHWAY Progressing toward commercial production equivalent units, clinical data collection, alongside validation and substantial equivalence testing Pre-hospital feasibility and usability studies with advanced prototype · Production equivalent device design and development · Data co
Slide 17: Commercialisation Drivers
COMMERCIALISATION DRIVERS Transitioning from R&D focus to market entry preparations • emu → De Novo Regulatory Clearance • First Responder → 510(k) • Australia and EU approvals post FDA Indicative Revenue Model Capital Consumables Servicing • Clinical & economic benefit evidence Reimbursement • Earl
Slide 18: Longer Term Growth Strategy
LONGER TERM GROWTH STRATEGY Initial US launch used as playbook for national scaling, geographic expansion and indication extension 1 US National Penetration 2 International Expansion 3 New Indications • Controlled national rollout, prioritising • Initially targeting European countries with • Traumat
Slide 19: Capital Structure
CAPITAL STRUCTURE Strong capital management track record ASX Ticker: EMV Historic Funding Sources Share Price (21 Aug 2026) $1.81 40 Shares on issue 92.9m 35 30 Total Options on issue 7.4m 25 Total Performance Rights on issue 0.3m A$ MILLION 20 Market Capitalisation $168m 15 10 Cash balance (30 Jun
EMVision Medical Devices — FY2026 Earnings Presentation on 6ix